17 news items
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
ZLAB
22 May 24
, Autoimmune & Infectious Diseases, Zai Lab. "ZL-1102 exemplifies the innovative, patient-focused R&D programs in our internal discovery
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
ZLAB
20 May 24
of XACDURO demonstrates Zai Lab's commitment to developing and delivering innovative therapies that address high unmet medical needs for patients
Zai Lab Announces Participation in May and June Investor Conferences
ZLAB
16 May 24
(NASDAQ:ZLAB, HKEX: 9688))) is an innovative, research-based, commercial-stage biopharmaceutical company based
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
ZLAB
14 May 24
capabilities and deep expertise developing and commercializing innovative treatments in China across a broad range of diseases
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPA
ZLAB
12 May 24
(NASDAQ:ZLAB, HKEX: 9688))) is an innovative, research-based, commercial-stage biopharmaceutical company
vsakkxqk2yz7u8iqsu
CRDF
JNJ
NTBL
9 May 24
the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer
nszs91f1sgu2bl686h n0gtvf43kh4q
ZLAB
15 Apr 24
Zai Lab (NASDAQ:ZLAB, HKEX: 9688))) is an innovative, research-based, commercial
tev9my1iu algt0oxwuoz7v3xw82jg5ot71
ZLAB
11 Apr 24
(NASDAQ:ZLAB, HKEX: 9688))) is an innovative, research-based, commercial-stage
w9ag8aubldecvrz80eh261d8jww 2045bo0yk8ocr9qh0k2
ZLAB
2 Apr 24
These internally discovered programs underscore the Company's focus on extending oncology R&D innovation to people with cancer worldwide
aiib bwrjw844mvulprk1etru
NVCR
ZLAB
27 Mar 24
))) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering
2dwt8w07tszn3gqk6aq9qwa85sp9m
ZLAB
14 Mar 24
launch in 2015, the company has brought more than 10 innovative drugs to the market, including pralsetinib, avapritinib, ivosidenib and sugemalimab
xiives08gv8y9m230tym2x3rrizjyge24ema2pa6qp0pzs
ZLAB
14 Mar 24
ZL-1310 is an innovative ADC targeting DLL3, a promising therapeutic target in small cell lung cancer and other DLL3+ solid tumors
9ian1utfa9v whmpshjmuuogkclk2s1n2ew1w
ZLAB
13 Mar 24
ZL-1310 is an innovative ADC targeting DLL3
3mc91ycz6bz2itj9ae5nrpw19xa8bwj46jzmvis2vpdq8bf4rcz9qz up
ZLAB
6 Mar 24
(NASDAQ:ZLAB, HKEX: 9688))) is an innovative, research-based, commercial-stage
nrozz1iimys95jd 23w4zry6bh2lehs9
ZLAB
6 Mar 24
Zai Lab (NASDAQ:ZLAB, HKEX: 9688))) is an innovative, research
0o98l6ce t78g8g46z2gowbr3t0473ezyqkst4gvg3osjak3kpapfu04
ZLAB
27 Feb 24
strategic plan and to position Zai Lab as a high-growth, profitable and innovative biotech company."
"We
cvzlqv5saqkqkcniy6le aaqap76wbep7l5atv2u39r
BILI
SDGR
ZH
25 Feb 24
backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX
- Prev
- 1
- Next